Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a NAD-Boosting supplement slow ALS? extension trial tests nicotinamide riboside and pterostilbene

NCT ID NCT05095571

NEW Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether a supplement combining nicotinamide riboside and pterostilbene (EH301) can slow the progression of amyotrophic lateral sclerosis (ALS) and extend survival. The study follows patients who completed the earlier NO-ALS trial, offering them open-label active treatment. The main goal is to monitor side effects and provide compassionate use, while also tracking changes in motor function and breathing capacity. About 300 patients will participate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a supplement combining nicotinamide riboside and pterostilbene (EH301)
What this could lead to
If the supplement helps, it could offer a low-cost way to slow ALS progression and extend survival, possibly adding years of better function for patients.
What could go wrong
ALS trials often fail, and this open-label extension has no placebo control, so any benefit could be due to chance or the placebo effect. High-dose supplements can cause side effects, and the results may not apply to all ALS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who fulfilled the criteria for the NO-ALS study and have completed the study will be proposed inclusion in the NO-ALS extension study protocol. Patients from both arm 1 and arm 2 in the NO-ALS study will be allowed inclusion in the prolongation study Exclusion Criteria: Individuals will be excluded if any of the following exclusion criteria apply: * Dementia, fronto temporal dementia (FTD) or other neurodegenerative disorder interfering with compliance. * Metabolic, neoplastic, or other physically or mentally debilitating disorder. * Patients who become tracheostomized as part of the treatment of ALS. * Patients with short expected survival at the discretion of the investigator. Such cases cannot be expected to follow protocol procedures. * Use of Vit B3 or blue berry extracts outside the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis

Contacts and locations

Locations

  • Akershus University Hospital

    Lørenskog, Norway

  • Haukeland University Hospital

    Bergen, Norway

  • Helse Fonna HF

    Haugesund, Norway

  • Helse Førde HF

    Førde, Norway

  • Helse Møre og Romsdal

    Molde, Norway

  • Helse Nord-Trøndelag HF

    Namsos, Norway

  • Nordlandssykehuset HF

    Bodø, Norway

  • Oslo Univerity Hospital

    Oslo, Norway

  • St. Olavs Hospital HF

    Trondheim, Norway

  • Stavanger University Hospital

    Stavanger, Norway

  • Sykehuset Innlandet HF

    Lillehammer, Norway

  • Sykehuset i Telemark HF

    Skien, Norway

  • Sykehuset i Vestfold HF

    Tønsberg, Norway

  • Sykehuset Østfold HF

    Sarpsborg, Norway

  • Sørlandet sykehus

    Kristiansand, Norway

  • Universitetssykehuset Nord-Norge

    Tromsø, Norway

  • Vestre Viken HF

    Drammen, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.